Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Pancreatic Neoplasms 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Carboplatin 103Pemetrexed 96pembrolizumab 78Docetaxel 78Cisplatin 72Paclitaxel 70Erlotinib Hydrochloride 50Gemcitabine 48Radiotherapy 42Nivolumab 35Bevacizumab 35atezolizumab 24Radiosurgery 24durvalumab 20Cyclophosphamide 17130-nm albumin-bound paclitaxel 15Vinorelbine 14Taxes 14Radiation 14Etoposide 13Ipilimumab 12Albumin-Bound Paclitaxel 12avelumab 11Drug Therapy 10Cetuximab 10spartalizumab 9Sorafenib 9trametinib 8osimertinib 8capmatinib 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Carcinoma, Non-Small-Cell Lung × Digoxin × Clear all
NCT00281021 2018-03-29

Second Line Erlotinib (Tarceva) Plus Digoxin in Non-Small Cell Lung Cancer

University of Louisville

Phase 2 Terminated
26 enrolled 5 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡